|
19 Oct 2007 |
Paion sees continued development rationale for Desmoteplase based on findings from phase III analysis
|
|
19 Oct 2007 |
Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
|
|
19 Oct 2007 |
Cleveland BioLabs Completes Manufacturing Process for Protectan CBLB502
|
|
19 Oct 2007 |
Nektar Therapeutics Issues Statement on Exubera
|
|
19 Oct 2007 |
SemBioSys confirms commercially viable levels of Native APO AI in safflower
|
|
19 Oct 2007 |
Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus(R)
|
|
18 Oct 2007 |
Omiganan Phase II Rosacea Study Demonstrates Promising Results
|
|
16 Oct 2007 |
Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
|
|
16 Oct 2007 |
Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
|
|
16 Oct 2007 |
NRP drug effective in animal models of motor neuron disease and peripheral neuropathy
|
|
13 Oct 2007 |
OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
|
|
13 Oct 2007 |
Long-Term Study Shows COPAXONE® Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients with Relapsing-Remitting Multiple Sclerosis
|
|
13 Oct 2007 |
Cyplasin-SC(TM) shows proof of efficacy in tumor bearing animals
|
|
12 Oct 2007 |
Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
|
|
12 Oct 2007 |
CuraGen Announces Top-Line Phase II Results on Velafermin
|
|
12 Oct 2007 |
Two-year Phase IIIb data show that the new formulation of Rebif® offers a near three-fold improvement in injection tolerability and reduced immunogenicity
|
|
12 Oct 2007 |
Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
|
|
12 Oct 2007 |
Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
|
|
12 Oct 2007 |
NascaCell Technologies AG and Boehringer Ingelheim sign collaboration agreement on therapeutic Microbodies(TM)
|
|
11 Oct 2007 |
Advitech Announces Positive Preclinical Results for Wound-Healing Application
|
|
11 Oct 2007 |
Biological Validation of Lead Compunds in Rheumatoid Arthritis Programme
|
|
09 Oct 2007 |
Jerini Initiates FDA Submission Process of New Drug Application for Icatibant in the Treatment of HAE
|
|
09 Oct 2007 |
Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels
|
|
06 Oct 2007 |
Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
|
|
06 Oct 2007 |
Genzyme Receives Approval to Market Elaprase(R) in Japan
|
